News Releases

Date Title and Summary Additional Formats
Toggle Summary Don Hardison Joins the Board of Directors for HTG Molecular Diagnostics
TUCSON, Ariz. , May 03, 2016 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that Donnie (Don) M. Hardison has been appointed to its Board of Directors (“Board”).
View HTML
Toggle Summary Dr. Ann Hanham Joins HTG Molecular Diagnostics’ Board of Directors
TUCSON, Ariz. , Aug. 29, 2016 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that Ann F. Hanham , Ph.D. has been appointed to its Board of Directors (“Board”).
View HTML
Toggle Summary HTG and MD Anderson Cancer Center Enter Into a Sponsored Research Agreement to Investigate New Molecular Diagnostics for Lung Cancer Using HTG's Next-Generation Sequencing Solution for Gene Expression
TUCSON, Ariz. , June 1, 2015 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications and The University of Texas MD Anderson Cancer Center have entered into a 2-year Sponsored Research Agreement to support
View HTML
Toggle Summary HTG Announces Completion of IVD Development and Supply Agreement With Illumina
Thursday, October 30, 2014 - 08:08 HTG Molecular Diagnostics, Inc. (HTG), a provider of instruments and reagents for molecular profiling applications, today announced that it entered into an agreement with Illumina, Inc. (NASDAQ:ILMN), under which HTG will have the right to develop
View HTML
Toggle Summary HTG Announces Issuance of Two Method Patents Related to its Technology
TUCSON, Ariz. , Sept. 20, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced the United States Patent and Trademark Office has issued two U.S.
View HTML
Toggle Summary HTG Announces New Australian Patent for Its Technology
Patent covers methods of co-detecting mRNA and small non-coding RNA TUCSON, Ariz. , Feb. 26, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced the issuance of Australian
View HTML
Toggle Summary HTG Announces New Patent for Its Technology Issued in Japan
Patent covers nuclease protection methods for detection of nucleotide variants   TUCSON, Ariz. , April 03, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced the issuance of
View HTML
Toggle Summary HTG Announces Preliminary Fourth Quarter and Full Year 2017 Unaudited Financial Results and Provides Initial 2018 Revenue Guidance
Fourth quarter 2017 revenue expected to be between $6.9 and $7.2 million Full year 2017 revenue expected to be between $13.8 and $14.1 million Initial full year 2018 revenue guidance of $20.0 to $25.0 million TUCSON, Ariz. , Jan. 04, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc.
View HTML
Toggle Summary HTG Edge System Wins 2013 Silver Medical Design Excellence Award
TUCSON, Ariz. (June, 2013) – The Edge System, developed and commercialized by HTG Molecular Diagnostics, is the 2013 Silver Award recipient for in-Vitro Diagnostics in the 15th Annual Medical Design Excellence Awards competition. The HTG Edge System is the only automated RNA analysis platform that
View HTML
Toggle Summary HTG Enters Worldwide Innovative Networking (WIN) Consortium for Personalized Cancer Medicine
TUCSON, Ariz. , Aug. 5, 2015 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications announced it has joined the Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine as an official
View HTML